Search results
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 6 days agoYou only have to find the right stocks worthy of holding for the long term and that pay attractive...
Abbvie Inc (ABBV) Becoming More Attractive for Investors – Knox Daily
Knox Daily· 4 days agoAbbvie Inc’s recent filing unveils that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24. In the deal ...
AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ...
GuruFocus.com via Yahoo Finance· 6 days agoAnd could you give us some confidence that you can continue to grow in '25 despite these headwinds from IRA and Humira? A: Robert A. Michael - AbbVie Inc. - President & COO ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 day agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth...
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates
Guru Focus· 7 days agoOn April 26, 2024, AbbVie Inc (ABBV, Financial) released its 8-K filing, detailing the financial outcomes for the first quarter ended March 31, 2024. The pharmaceutical giant ...
Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Medscape· 10 hours agoRecent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK...
AbbVie raises earnings forecast on strong immunology drug growth
Crain s Chicago Business· 7 days agoThe growth helped offset sales declines of Humira, AbbVie’s once best-selling immunosuppressive medication that began facing biosimilar competition last year. Humira sales ...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 23 hours agoThe treatment, Elahere (mirvetuximab soravtansine), is for patients with late-stage disease who have...
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
Market Watch· 7 days agoShares of AbbVie lost 4.6% to close at $159.62 on Friday after the company warned about the effects of losing the exclusivity of its patent for the arthritis medication Humira ...
PCE/Core PCE Numbers Came In Line With Expectations
Zacks via Yahoo Finance· 7 days agoSo while we see progress on inflation having become stagnant — in this and other economic data out this month — these are far from the fearful numbers...
